🇺🇸 FDA
Patent

US 10836741

Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

granted A61PA61P1/04A61P13/12

Quick answer

US patent 10836741 (Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors) held by Valo Early Discovery, Inc. expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Valo Early Discovery, Inc.
Grant date
Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61P, A61P1/04, A61P13/12, A61P21/02, A61P25/00